Loading…

Subtypes of antipsychotics and suicidal behavior in bipolar disorder

Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2012-12, Vol.143 (1), p.27-33
Main Authors: Koek, Ralph J, Yerevanian, Boghos I, Mintz, Jim
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3
cites cdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3
container_end_page 33
container_issue 1
container_start_page 27
container_title Journal of affective disorders
container_volume 143
creator Koek, Ralph J
Yerevanian, Boghos I
Mintz, Jim
description Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.
doi_str_mv 10.1016/j.jad.2012.05.053
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1364765610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032712004363</els_id><sourcerecordid>1272723519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhoMo7rj6A7xIXwQvPVaSzheCIOsnLHhYPYd0usJm7Om0SffC_HszzKjgwSUFIfC8lZCnCHlOYUuByte77c4NWwaUbUHU4g_IhgrFWyaoekg2lREtcKYuyJNSdgAgjYLH5IIx1ZlKbsj7m7VfDjOWJoXGTUucy8HfpiX6Uo9DU9bo4-DGpsdbdxdTbuLU9HFOo8vNEEvKA-an5FFwY8Fn5_2SfP_44dvV5_b666cvV--uWy-4WlpNQwfUB8Ul152D0OvQMXCd1tohBmmEVE5oZEZxY3hvek6BGY8cayDwS_Lq1HfO6eeKZbH7WDyOo5swrcVSLjslhaRwP8pUXVxQcz9KlZYadEcrSk-oz6mUjMHOOe5dPlgK9qjE7mxVYo9KLIhavGZenNuv_R6HP4nfDirw8gy44t0Yspt8LH85KTtjJKvcmxOH9YvvImZbfMTJ4xAz-sUOKf73GW__SfsxTrFe-AMPWHZpzVN1Z6ktNWNvjrNzHB3KALoqjP8Cke27fw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1178680841</pqid></control><display><type>article</type><title>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Elsevier</source><creator>Koek, Ralph J ; Yerevanian, Boghos I ; Mintz, Jim</creator><creatorcontrib>Koek, Ralph J ; Yerevanian, Boghos I ; Mintz, Jim</creatorcontrib><description>Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.</description><identifier>ISSN: 0165-0327</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2012.05.053</identifier><identifier>PMID: 22749157</identifier><identifier>CODEN: JADID7</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Affective disorders ; Aged ; Anticonvulsants ; Anticonvulsants - therapeutic use ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Antipsychotics ; Attempted suicide ; Benzodiazepines - therapeutic use ; Biological and medical sciences ; Bipolar affective disorder ; Bipolar disorder ; Bipolar Disorder - drug therapy ; Bipolar disorders ; Carbamazepine ; Conjunction ; Data processing ; Depression ; Dibenzothiazepines - therapeutic use ; Divalproex ; Female ; Hospitalization ; Hospitals ; Humans ; Lithium ; Male ; Medical sciences ; Middle Aged ; Mood ; Mood disorders ; Moods ; Neuroleptics ; Neuropharmacology ; olanzapine ; Pharmacology. Drug treatments ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; quetiapine ; Quetiapine Fumarate ; Retrospective Studies ; Risk factors ; Risperidone ; Risperidone - therapeutic use ; Suicidal behaviour ; Suicidal Ideation ; Suicide ; Suicide - prevention &amp; control ; Suicide - psychology ; Suicide - statistics &amp; numerical data ; Suicide, Attempted - prevention &amp; control ; Suicide, Attempted - psychology ; Suicide, Attempted - statistics &amp; numerical data ; Veterans</subject><ispartof>Journal of affective disorders, 2012-12, Vol.143 (1), p.27-33</ispartof><rights>2012</rights><rights>2015 INIST-CNRS</rights><rights>Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</citedby><cites>FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,31000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26649962$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22749157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koek, Ralph J</creatorcontrib><creatorcontrib>Yerevanian, Boghos I</creatorcontrib><creatorcontrib>Mintz, Jim</creatorcontrib><title>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Affective disorders</subject><subject>Aged</subject><subject>Anticonvulsants</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Antipsychotics</subject><subject>Attempted suicide</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bipolar affective disorder</subject><subject>Bipolar disorder</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Bipolar disorders</subject><subject>Carbamazepine</subject><subject>Conjunction</subject><subject>Data processing</subject><subject>Depression</subject><subject>Dibenzothiazepines - therapeutic use</subject><subject>Divalproex</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Lithium</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood</subject><subject>Mood disorders</subject><subject>Moods</subject><subject>Neuroleptics</subject><subject>Neuropharmacology</subject><subject>olanzapine</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>quetiapine</subject><subject>Quetiapine Fumarate</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Risperidone</subject><subject>Risperidone - therapeutic use</subject><subject>Suicidal behaviour</subject><subject>Suicidal Ideation</subject><subject>Suicide</subject><subject>Suicide - prevention &amp; control</subject><subject>Suicide - psychology</subject><subject>Suicide - statistics &amp; numerical data</subject><subject>Suicide, Attempted - prevention &amp; control</subject><subject>Suicide, Attempted - psychology</subject><subject>Suicide, Attempted - statistics &amp; numerical data</subject><subject>Veterans</subject><issn>0165-0327</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqFkk2LFDEQhoMo7rj6A7xIXwQvPVaSzheCIOsnLHhYPYd0usJm7Om0SffC_HszzKjgwSUFIfC8lZCnCHlOYUuByte77c4NWwaUbUHU4g_IhgrFWyaoekg2lREtcKYuyJNSdgAgjYLH5IIx1ZlKbsj7m7VfDjOWJoXGTUucy8HfpiX6Uo9DU9bo4-DGpsdbdxdTbuLU9HFOo8vNEEvKA-an5FFwY8Fn5_2SfP_44dvV5_b666cvV--uWy-4WlpNQwfUB8Ul152D0OvQMXCd1tohBmmEVE5oZEZxY3hvek6BGY8cayDwS_Lq1HfO6eeKZbH7WDyOo5swrcVSLjslhaRwP8pUXVxQcz9KlZYadEcrSk-oz6mUjMHOOe5dPlgK9qjE7mxVYo9KLIhavGZenNuv_R6HP4nfDirw8gy44t0Yspt8LH85KTtjJKvcmxOH9YvvImZbfMTJ4xAz-sUOKf73GW__SfsxTrFe-AMPWHZpzVN1Z6ktNWNvjrNzHB3KALoqjP8Cke27fw</recordid><startdate>20121220</startdate><enddate>20121220</enddate><creator>Koek, Ralph J</creator><creator>Yerevanian, Boghos I</creator><creator>Mintz, Jim</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>7QJ</scope></search><sort><creationdate>20121220</creationdate><title>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</title><author>Koek, Ralph J ; Yerevanian, Boghos I ; Mintz, Jim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Affective disorders</topic><topic>Aged</topic><topic>Anticonvulsants</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Antipsychotics</topic><topic>Attempted suicide</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bipolar affective disorder</topic><topic>Bipolar disorder</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Bipolar disorders</topic><topic>Carbamazepine</topic><topic>Conjunction</topic><topic>Data processing</topic><topic>Depression</topic><topic>Dibenzothiazepines - therapeutic use</topic><topic>Divalproex</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Lithium</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood</topic><topic>Mood disorders</topic><topic>Moods</topic><topic>Neuroleptics</topic><topic>Neuropharmacology</topic><topic>olanzapine</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>quetiapine</topic><topic>Quetiapine Fumarate</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Risperidone</topic><topic>Risperidone - therapeutic use</topic><topic>Suicidal behaviour</topic><topic>Suicidal Ideation</topic><topic>Suicide</topic><topic>Suicide - prevention &amp; control</topic><topic>Suicide - psychology</topic><topic>Suicide - statistics &amp; numerical data</topic><topic>Suicide, Attempted - prevention &amp; control</topic><topic>Suicide, Attempted - psychology</topic><topic>Suicide, Attempted - statistics &amp; numerical data</topic><topic>Veterans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koek, Ralph J</creatorcontrib><creatorcontrib>Yerevanian, Boghos I</creatorcontrib><creatorcontrib>Mintz, Jim</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koek, Ralph J</au><au>Yerevanian, Boghos I</au><au>Mintz, Jim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subtypes of antipsychotics and suicidal behavior in bipolar disorder</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2012-12-20</date><risdate>2012</risdate><volume>143</volume><issue>1</issue><spage>27</spage><epage>33</epage><pages>27-33</pages><issn>0165-0327</issn><eissn>1573-2517</eissn><coden>JADID7</coden><abstract>Abstract Objective Antipsychotics are commonly used in bipolar disorder, with newer (SGA) agents increasingly replacing FGA antipsychotics, particularly in bipolar depression. There are few data on differences between FGA and SGA antipsychotics in terms of their relationship to suicidal behavior in bipolar disorder. Method This was a retrospective chart review of 161 bipolar veterans treated naturalistically with antipsychotics at a university-affiliated VA hospital and clinics for up to 8 years. Charts were reviewed to determine monthly antipsychotic use and occurrence of suicidal behavior: completed suicide, attempted suicide or hospitalization to prevent suicide. Suicidal behavior events were compared across patients during treatment with individual antipsychotics and FGAs or SGAs as a class. Results Non-lethal suicide events were more common during FGA than SGA monotherapy (9 events/110 months of exposure vs. 6 events/381 months of exposure; χ2 =9.65, p =0.002). Suicide event rates did not differ between FGAs and SGAs when used in conjunction with mood stabilizers. Event rates were lower with lithium than anticonvulsants when used in conjunction with antipsychotics. No differences were found between olanzapine, risperidone and quetiapine. Limitations The retrospective chart review methodology may have led to confounding by indication and diagnostic inaccuracy. No completed suicides occurred. Study participants were primarily male veterans. Results may not be generalizable to SGAs marketed since 2003. Conclusions FGA antipsychotic monotherapy may be associated with higher suicidal behavior risk than SGA antipsychotic monotherapy. Antipsychotics used in conjunction with mood stabilizers, particularly lithium, are associated with lower rates, independent of antipsychotic subtype.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>22749157</pmid><doi>10.1016/j.jad.2012.05.053</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-0327
ispartof Journal of affective disorders, 2012-12, Vol.143 (1), p.27-33
issn 0165-0327
1573-2517
language eng
recordid cdi_proquest_miscellaneous_1364765610
source Applied Social Sciences Index & Abstracts (ASSIA); Elsevier
subjects Adult
Adult and adolescent clinical studies
Affective disorders
Aged
Anticonvulsants
Anticonvulsants - therapeutic use
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Antipsychotics
Attempted suicide
Benzodiazepines - therapeutic use
Biological and medical sciences
Bipolar affective disorder
Bipolar disorder
Bipolar Disorder - drug therapy
Bipolar disorders
Carbamazepine
Conjunction
Data processing
Depression
Dibenzothiazepines - therapeutic use
Divalproex
Female
Hospitalization
Hospitals
Humans
Lithium
Male
Medical sciences
Middle Aged
Mood
Mood disorders
Moods
Neuroleptics
Neuropharmacology
olanzapine
Pharmacology. Drug treatments
Psychiatry
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
quetiapine
Quetiapine Fumarate
Retrospective Studies
Risk factors
Risperidone
Risperidone - therapeutic use
Suicidal behaviour
Suicidal Ideation
Suicide
Suicide - prevention & control
Suicide - psychology
Suicide - statistics & numerical data
Suicide, Attempted - prevention & control
Suicide, Attempted - psychology
Suicide, Attempted - statistics & numerical data
Veterans
title Subtypes of antipsychotics and suicidal behavior in bipolar disorder
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subtypes%20of%20antipsychotics%20and%20suicidal%20behavior%20in%20bipolar%20disorder&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Koek,%20Ralph%20J&rft.date=2012-12-20&rft.volume=143&rft.issue=1&rft.spage=27&rft.epage=33&rft.pages=27-33&rft.issn=0165-0327&rft.eissn=1573-2517&rft.coden=JADID7&rft_id=info:doi/10.1016/j.jad.2012.05.053&rft_dat=%3Cproquest_cross%3E1272723519%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c537t-81f401cf736384a0fb8f420a4888aeef69567a58e2973993b9b31029ce3e384f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1178680841&rft_id=info:pmid/22749157&rfr_iscdi=true